Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations

European Journal of Haematology

Volumn 84, Issue 1, 2010, Pages 87-88

  He, Yanli ^a   Zheng, Jine ^a   Hu, Yanjie ^a   Xiao, Hong ^a   Liu, Jun ^a   Li, Xiaoqing ^a   Du, Wen ^a   Chen, Xiangjun ^a   Hu, Yu ^b   Huang, Shiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Tongji Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; IMATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLECKSTRIN; PROTEIN KINASE B; RAPAMYCIN; SERINE; THREONINE;

AMINO ACID SUBSTITUTION; BLAST CELL CRISIS; CANCER RESISTANCE; CANCER SCREENING; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA EXTRACTION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LETTER; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION, MISSENSE; NEOPLASM PROTEINS; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES;

EID: 72449200714     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01350.x     Document Type: Letter

References (13)

1. Vivanco I, Sawyers CL. The phosphatidyl inositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002 2 : 489 501.
2. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007 129 : 1261 1274.
3. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008 47 : 363 367.
4. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007 448 : 439 444.
5. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008 98 : 1533 1535.
6. Zenz T, Dohner K, Denzel T, Dohner H, Stilgenbauer S, Bullinger L. PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol 2008 140 : 344 347.
7. Schuller U, Ruiter M, Herms J, Kretzschmar HA, Grasbon-Frodl E. Absence of mutations in the AKT1 oncogene in glioblastomas and medulloblastomas. Acta Neuropathol 2008 115 : 367 368.
8. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008 7 : 665 669.
9. Riener M-O, Bawohl M, Clavien P-A, Jochum W. Analysis of oncogenic AKT1 p.E17K mutation in carcinomas of the biliary tract and liver. Br J Cancer 2008 99 : 836.
10. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005 5 : 172 183.
11. Epner DE, Koeffler HP. Molecular genetic advances in 34 chronic myelogenous leukemia. Ann Intern Med 1990 113 : 3 6.
12. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S, Wymann MP, Brosens JJ, Schulze A, Lam EW. The forkhead transcription factor FOXO3a increases PI3K/Akt activity in drug-resistant leukaemic cells through induction of PIK3CA expression. Mol Cell Biol 2008 28 : 5886 5898.
13. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006 66 : 6468 6472. (Pubitemid 44085597)